Ally Bridge Group (NY) LLC reported 20 positions worth $67.10M for the quarter ended Jun 30, 2026, down 20.0% on the prior quarter. It opened 9 new positions, added to 1, trimmed 8 and exited 7. Its largest holding is Minerva Neurosciences, Inc. at 18% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| TRAX First Tracks Biotherapeutics, Inc. | +284.3K | – | $5.72M | 8.52% |
| AXSM Axsome Therapeutics, Inc. | +16.5K | – | $4.04M | 6.02% |
| ASMB Assembly Biosciences, Inc. | +140.0K | – | $3.85M | 5.73% |
| CLYM Climb Bio, Inc. | +249.2K | – | $3.25M | 4.84% |
| KURA Kura Oncology, Inc. | +290.0K | – | $3.18M | 4.74% |
| NERV Minerva Neurosciences, Inc. | +520.3K | +31.4% | $2.89M | 18% |
| AVTX Avalo Therapeutics, Inc. | +150.0K | – | $2.77M | 4.13% |
| PALI Palisade Bio, Inc. | +1.23M | – | $2.57M | 3.83% |
| IDYA IDEAYA Biosciences, Inc. | +67.5K | – | $2.52M | 3.75% |
| IBIO iBio, Inc. | +390.1K | – | $682.76K | 1.02% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| PRAX Praxis Precision Medicines, Inc. | -32.8K | -100.0% | $10.57M | Exited |
| OVID Ovid Therapeutics Inc. | -2.19M | -77.8% | $5.90M | 2.5% |
| CMPS COMPASS Pathways plc | -1.05M | -100.0% | $5.78M | Exited |
| TARS Tarsus Pharmaceuticals, Inc. | -80.9K | -100.0% | $5.67M | Exited |
| SLDB Solid Biosciences Inc. | -511.0K | -66.6% | $5.11M | 3.81% |
| URGN UroGen Pharma Ltd. | -132.9K | -65.8% | $4.89M | 3.79% |
| ABVX Abivax S.A. | -33.7K | -100.0% | $3.75M | Exited |
| CAPR Capricor Therapeutics, Inc. | -113.9K | -100.0% | $3.46M | Exited |
| EWTX Edgewise Therapeutics, Inc. | -77.7K | -48.3% | $3.16M | 5.04% |
| ALMS Alumis Inc. | -90.5K | -54.2% | $2.55M | 3.21% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| TRAX First Tracks Biotherapeutics, Inc. | +284.3K | $5.72M | 8.52% |
| AXSM Axsome Therapeutics, Inc. | +16.5K | $4.04M | 6.02% |
| ASMB Assembly Biosciences, Inc. | +140.0K | $3.85M | 5.73% |
| CLYM Climb Bio, Inc. | +249.2K | $3.25M | 4.84% |
| KURA Kura Oncology, Inc. | +290.0K | $3.18M | 4.74% |
| AVTX Avalo Therapeutics, Inc. | +150.0K | $2.77M | 4.13% |
| PALI Palisade Bio, Inc. | +1.23M | $2.57M | 3.83% |
| IDYA IDEAYA Biosciences, Inc. | +67.5K | $2.52M | 3.75% |
| IBIO iBio, Inc. | +390.1K | $682.76K | 1.02% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| PRAX Praxis Precision Medicines, Inc. | -32.8K | $10.57M | 12.6% |
| CMPS COMPASS Pathways plc | -1.05M | $5.78M | 6.89% |
| TARS Tarsus Pharmaceuticals, Inc. | -80.9K | $5.67M | 6.76% |
| ABVX Abivax S.A. | -33.7K | $3.75M | 4.47% |
| CAPR Capricor Therapeutics, Inc. | -113.9K | $3.46M | 4.13% |
| IKT Inhibikase Therapeutics, Inc. | -1.33M | $2.23M | 2.65% |
| RLMD Relmada Therapeutics, Inc. | -210.5K | $1.47M | 1.75% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | NERV Minerva Neurosciences, Inc. | Healthcare | 2.18M | $12.08M | 18% | +520.3K | +31.4% | Added | 4.61% |
| 2 | TRAX First Tracks Biotherapeutics, Inc. | Healthcare | 284.3K | $5.72M | 8.52% | +284.3K | – | New | 0.8% |
| 3 | AXSM Axsome Therapeutics, Inc. | Healthcare | 16.5K | $4.04M | 6.02% | +16.5K | – | New | 0.03% |
| 4 | ASMB Assembly Biosciences, Inc. | Healthcare | 140.0K | $3.85M | 5.73% | +140.0K | – | New | 0.71% |
| 5 | WHWK Whitehawk Therapeutics, Inc. | Healthcare | 817.9K | $3.75M | 5.58% | 0 | 0.0% | Unchanged | 0.99% |
| 6 | EWTX Edgewise Therapeutics, Inc. | Healthcare | 83.3K | $3.38M | 5.04% | -77.7K | -48.3% | Reduced | 0.08% |
| 7 | CLYM Climb Bio, Inc. | Healthcare | 249.2K | $3.25M | 4.84% | +249.2K | – | New | 0.33% |
| 8 | KURA Kura Oncology, Inc. | Healthcare | 290.0K | $3.18M | 4.74% | +290.0K | – | New | 0.33% |
| 9 | CTMX CytomX Therapeutics, Inc. | Healthcare | 775.0K | $2.91M | 4.33% | -125.0K | -13.9% | Reduced | 0.35% |
| 10 | AVTX Avalo Therapeutics, Inc. | Healthcare | 150.0K | $2.77M | 4.13% | +150.0K | – | New | 0.28% |
| 11 | PALI Palisade Bio, Inc. | Healthcare | 1.23M | $2.57M | 3.83% | +1.23M | – | New | 0.58% |
| 12 | SLDB Solid Biosciences Inc. | Healthcare | 256.0K | $2.56M | 3.81% | -511.0K | -66.6% | Reduced | 0.18% |
| 13 | ANTX AN2 Therapeutics, Inc. | Healthcare | 526.3K | $2.55M | 3.8% | 0 | 0.0% | Unchanged | 1.18% |
| 14 | URGN UroGen Pharma Ltd. | Healthcare | 69.2K | $2.55M | 3.79% | -132.9K | -65.8% | Reduced | 0.14% |
| 15 | CATX Perspective Therapeutics, Inc. | Healthcare | 744.0K | $2.54M | 3.78% | -182.6K | -19.7% | Reduced | 0.62% |
Tip. Select a row to see that position’s full history at Ally Bridge Group (NY).
As of its Q2 2026 13F filing, Ally Bridge Group (NY) LLC’s five largest positions were Minerva Neurosciences, Inc. (NERV) at 18.0%, First Tracks Biotherapeutics, Inc. (TRAX) at 8.5%, Axsome Therapeutics, Inc. (AXSM) at 6.0%, Assembly Biosciences, Inc. (ASMB) at 5.7%, Whitehawk Therapeutics, Inc. (WHWK) at 5.6% of the reported portfolio.
Ally Bridge Group (NY) LLC reported a 13F portfolio worth $67.10M across 20 positions for Q2 2026. That is down 20.0% from the previous quarter.
Its largest purchases by value were First Tracks Biotherapeutics, Inc. ($5.72M), Axsome Therapeutics, Inc. ($4.04M), Assembly Biosciences, Inc. ($3.85M). It opened 9 new positions.
Its largest sales by value were Praxis Precision Medicines, Inc. ($10.57M), Ovid Therapeutics Inc. ($5.90M), COMPASS Pathways plc ($5.78M). It exited 7 positions entirely.
From the Form 13F-HR reports Ally Bridge Group (NY) LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.